Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 11, 1999, Pages 1481-1491

  Escourrou, J ^a   Deprez, P ^b   Saggioro, A ^c   Geldof, H ^d   Fischer, R ^e   Maier, C ^e  

^a CHU RANGUEIL   (France)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c Ospedale Umberto I   (Italy)

^d IJSSELLAND HOSPITAL   (Netherlands)

^e ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PANTOPRAZOLE; STOMACH SECRETION INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RELAPSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FEMALE; GASTRINS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; PROTON PUMPS; RECURRENCE; SULFOXIDES;

EID: 0032702404     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00651.x     Document Type: Article

References (36)

1. 1 Penston JG, Pounder RE. A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther 1996; 10: 83-9.
2. 2 Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
3. 3 Richter JE. Long-term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol 1997; 92: S30-4.
4. 4 Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.
5. 5 Moss SF, Arnold R, Tytgat, GNJ, et al. Consensus statement for management of gastroesophageal reflux disease. J Clin Gastroenterol 1998; 27: 6-12.
6. 6 Savary M, Miller G (eds). The esophagus. In: Handbook and Atlas of Endoscopy. Switzerland: Verlag Gassman AG, 1978: 119-205.
7. 7 Mössner J. Hölscher AH, Herz R, et al. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9: 321-6.
8. 8 Corinaldesi R, Valentini M, Belaiche J, et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther 1995; 9: 667-71.
9. 9 Koop H, Schepp W, Dammann HG, et al. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study. J Clin Gastroenterol 1995; 20: 192-5.
10. 10 Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51: 460-82.
11. 11 Chiba N. De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
12. 12 Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997; 11(Suppl. B): B66-73.
13. 13 Boyce HW. Therapeutic approaches to healing esophagitis. Am J Gastroenterol 1997; 92: S22-7.
14. 14 Fennerty MB, Lieberman D. H2-receptor antagonists in the treatment of complicated gastroesophageal reflux disease; 'for whom the bell tolls'. Gastroenterology 1994; 107: 1545-8.
15. 15 Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56: 307-35.
16. 16 Lundell L. Long-term treatment of gastro-oesophageal reflux disease with omeprazole. Scand J Gastroenterol Suppl. 1994; 201: 74-8.
17. 17 Robinson M, Lanza F, Avner D, et al. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124: 859-67.
18. 18 Reynolds JC. Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease. Am J Health Syst. Pharm 1996; 51: S5-12.
19. 19 Bate CM, Green JR, Axon AT, et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastrooesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 1997; 11: 755-63.
20. 20 Johnson DA. Medical therapy of GERD: current state of the art. Hosp Pract 1996; 31: 135-48.
21. 21 Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 529-39.
22. 22 Venables TL, Newland RD, Patel AC, et al. Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol 1997; 32: 627-32.
23. 23 Hatlebakk JG, Berstad A. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. Aliment Pharmacol Ther 1997; 11: 1093-9.
24. 24 Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 1996; 34: S31-50.
25. 25 Johansson KE, Boeryd B, Johansson K, et al. Double-blind crossover study of ranitidine and placebo in gastro-oesophageal reflux disease. Scand J Gastroenterol 1986; 21: 769-78.
26. 26 Havelund T, Laursen LS, Lauritsen K. Ellicacy of omeprazole in lower grades of gastro-oesophageal reflux disease. Scand J Gastroenterol Suppl. 1994; 201: 69-73.
27. 27 Bardhan KD. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy - a sideways glance. Yale J Biol Med 1996; 69: 211-24.
28. 28 Hallerbäck B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994; 107: 1305-11.
29. 29 Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. Gut 1995; 36: 492-8.
30. 50 Laursen LS, Havelund T, Bondesen S, et al. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. Scand J Gastroenterol 1995; 30: 839-46.
31. 31 Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590-8.
32. 32 Hatlebakk JG, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 1997; 11: 565-72.
33. 33 Mössner J, Koop H, Porst H, et al. One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux in patients with healed reflux oesophagitis. Aliment Pharmacol Ther 1997; 11: 1087-92.
34. 54 Plein K, Hotz J, Wurzer H, et al. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 1999, in press.
35. 35 Freston JW, Malagelada JR, Petersen H, et al. Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 1995; 7: 577-86.
36. 36 Beck IT, Champion MC, Lemire S, et al. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. Can J Gastroenterol 1997; 11(Suppl. B): B7-20.